Kirsten Harvey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kirsten Harvey has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Leila Saiepour
The **Department of Neuroscience, Physiology, and Pharmacology, University College London, London WC1E 6BT, United Kingdom
2 shared publications- Robert J. Harvey
School of Health, University of the Sunshine Coast
2 shared publications Annarita Patrizi
The §Department of Anatomy, Pharmacology, and Forensic Medicine, National Institute of Neuroscience-Italy, University of Turin, C.so Massimo d'Azeglio 52, 10126 Turin, Italy
1 shared publication- Bernard Man Hin Law
The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
1 shared publication Bernd Kerschner
The **Department of Neuroscience, Physiology, and Pharmacology, University College London, London WC1E 6BT, United Kingdom
1 shared publicationCeline Fuchs
The §Department of Anatomy, Pharmacology, and Forensic Medicine, National Institute of Neuroscience-Italy, University of Turin, C.so Massimo d'Azeglio 52, 10126 Turin, Italy
1 shared publication
Latest Publications
- Open Access
- 1 October 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (43) , 37702-37711
Molecular Basis of the γ-Aminobutyric Acid A Receptor α3 Subunit Interaction with the Clustering Protein Gephyrin
- 1 October 2011
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 286 (43) , 37702-37711
Open AccessMolecular Basis of the γ-Aminobutyric Acid A Receptor α3 Subunit Interaction with the Clustering Protein Gephyrin
- Open Access
- 1 September 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (38) , 29623-29631
Complex Role of Collybistin and Gephyrin in GABAA Receptor Clustering
- 1 September 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (38) , 29623-29631
Open AccessComplex Role of Collybistin and Gephyrin in GABAA Receptor Clustering
- Open Access
- 22 July 2009
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 18 (20) , 3955-3968
Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways
Mutations in PARK8, encoding LRRK2, are the most common known cause of Parkinson's disease. The LRRK2 Roc-COR tandem domain exhibits GTPase activity controlling LRRK2 kinase activity via an intramolecular process. We report the interaction of LRRK2 with the dishevelled family of phosphoproteins (DVL1-3), key regulators of Wnt (Wingless/Int) signalling pathways important for axon guidance, synapse formation and neuronal maintenance. Interestingly, DVLs can interact with and mediate the activation of small GTPases with structural similarity to the LRRK2 Roc domain. The LRRK2 Roc-COR domain and the DVL1 DEP domain were necessary and sufficient for LRRK2–DVL1 interaction. Co-expression of DVL1 increased LRRK2 steady-state protein levels, an effect that was dependent on the DEP domain. Strikingly, LRRK2–DVL1-3 interactions were disrupted by the familial PARK8 mutation Y1699C, whereas pathogenic mutations at residues R1441 and R1728 strengthened LRRK2–DVL1 interactions. Co-expression of DVL1 with LRRK2 in mammalian cells resulted in the redistribution of LRRK2 to typical cytoplasmic DVL1 aggregates in HEK293 and SH-SY5Y cells and co-localization in neurites and growth cones of differentiated dopaminergic SH-SY5Y cells. This is the first report of the modulation of a key LRRK2-accessory protein interaction by PARK8 Roc-COR domain mutations segregating with Parkinson's disease. Since the DVL1 DEP domain is known to be involved in the regulation of small GTPases, we propose that: (i) DVLs may influence LRRK2 GTPase activity, and (ii) Roc-COR domain mutations modulating LRRK2–DVL interactions indirectly influence kinase activity. Our findings also link LRRK2 to Wnt signalling pathways, suggesting novel pathogenic mechanisms and new targets for genetic analysis in Parkinson's disease.
- 22 July 2009
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 18 (20) , 3955-3968
Open AccessMutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways
Mutations in PARK8, encoding LRRK2, are the most common known cause of Parkinson's disease. The LRRK2 Roc-COR tandem domain exhibits GTPase activity controlling LRRK2 kinase activity via an intramolecular process. We report the interaction of LRRK2 with the dishevelled family of phosphoproteins (DVL1-3), key regulators of Wnt (Wingless/Int) signalling pathways important for axon guidance, synapse formation and neuronal maintenance. Interestingly, DVLs can interact with and mediate the activation of small GTPases with structural similarity to the LRRK2 Roc domain. The LRRK2 Roc-COR domain and the DVL1 DEP domain were necessary and sufficient for LRRK2–DVL1 interaction. Co-expression of DVL1 increased LRRK2 steady-state protein levels, an effect that was dependent on the DEP domain. Strikingly, LRRK2–DVL1-3 interactions were disrupted by the familial PARK8 mutation Y1699C, whereas pathogenic mutations at residues R1441 and R1728 strengthened LRRK2–DVL1 interactions. Co-expression of DVL1 with LRRK2 in mammalian cells resulted in the redistribution of LRRK2 to typical cytoplasmic DVL1 aggregates in HEK293 and SH-SY5Y cells and co-localization in neurites and growth cones of differentiated dopaminergic SH-SY5Y cells. This is the first report of the modulation of a key LRRK2-accessory protein interaction by PARK8 Roc-COR domain mutations segregating with Parkinson's disease. Since the DVL1 DEP domain is known to be involved in the regulation of small GTPases, we propose that: (i) DVLs may influence LRRK2 GTPase activity, and (ii) Roc-COR domain mutations modulating LRRK2–DVL interactions indirectly influence kinase activity. Our findings also link LRRK2 to Wnt signalling pathways, suggesting novel pathogenic mechanisms and new targets for genetic analysis in Parkinson's disease.